Investment & Partnering
ARAIM is a privately held clinical stage pharmaceutical company developing treatments for Neurology and Diabetes related disorders through a proprietary novel platform technology. ARAIMs lead asset, Cibinetide, is in Phase 2 to delay disease progression and manage pain associated with Diabetic Neuropathy and Neuropathy associated with Sarcoidosis.
ARAIM has benefitted from collaborating with leading academic researchers from renowned research institutions in developing the scientific foundations for our platform. As we progress towards the patient, we are actively seeking collaboration from academic researchers, biopharmaceutical companies, and investors
For investment considerations please contact Investors@araimpharma.com
For partnering considerations please contact PharmaPartners@araimpharma.com
For research considerations please contact Research@araimpharma.com
Araim Scientific Platform has been investigated in collaboration with an extensive network of leading global academic research scientists
| Sarcoidosis | Daniel Culver | Cleveland Clinic |
| Diabetic Neuropathy | Robert Schmidt | Washington University School of Medicine |
| Diabetic Retinopathy | Alan Stitt | Queen’s University, Belfast |
| Neuropathy | Rayaz Malik | Weill Cornell Medicine-Qatar |
| Pain & Neuropathy | Albert Dahan | Leiden University Medical Center |
| Diabetes | Claes-Göran Östenson | Karolinska Institute |
| Pain Biomarkers | Torsten Gordh | Uppsala University |
| Heart Disease | Masanobu Kawakami | Jichi Medical University |
| Aging | Edward Lakatta | National Institute on Aging |
| Kidney Injury | Christoph Theimermann | William Harvey Research Institute |
| Burn Injury | Martin Yarmush | Harvard Medical School |
| Alzheimer’s Disease | Michael Bacher | University of Marburg |
| Islet Transplantation | Torbjörn Lundgren | Karolinska Institute |
| Traumatic Brain Injury | Claudia Robertson | Baylor College of Medicine |
| Epilepsy | Nihal de Lanerolle | Yale University School of Medicine |
| Inflammatory Bowel Disease | Gunther Weiss | Medical University of Innsbruck |
Extensive research has resulted in >70 peer-reviewed scientific publications.